Folinic Acid
Folinic Acid is a pharmaceutical drug with 87 clinical trials. Currently 14 active trials ongoing. Historical success rate of 82.1%.
Success Metrics
Based on 46 completed trials
Phase Distribution
Phase Distribution
12
Early Stage
54
Mid Stage
18
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.7%
46 of 57 finished
19.3%
11 ended early
14
trials recruiting
87
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
A Placebo-controlled Trial of Folinic Acid in Children With ASD
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Clinical Trials (87)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
A Placebo-controlled Trial of Folinic Acid in Children With ASD
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Folinic Acid as a Treatment for Autism Spectrum Disorder in Children
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder
Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
The Sagittarius Trial
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 87